151
|
Abstract
Multiple myeloma (MM) remains essentially incurable by conventional anti-tumour therapy. This has led to increased interest in the possibility that forms of immune therapy might be effective. The successful use of donor lymphocyte infusions (DLI) in a few cases of MM relapse following allogeneic bone marrow transplantation have added weight to this view. MM is characterized by several defects in the host's immune system. The influence of the malignant clone on the function of the immune effector cells results from both passive and active suppression. Despite an array of functional adhesion molecules and HLA class I and II molecules on their surface and the secretion of a tumour-specific peptide, they fail to express adequate levels of co-stimulatory molecules thus inducing anergy in potentially tumour-specific T cells. In addition to this passive evasion of immune regulation, MM tumour cells are capable of producing a number of immunologically active agents which can induce immunosuppression such as transforming growth factor-beta, Fas ligand (FasL), vascular endothelial growth factor and Muc-1. It is postulated that these agents may be produced by the tumour cell to influence the microenvironment to support growth and differentiation of the clone but may have the additional benefit of altering the function of the host immune effector cells and thus preventing tumour rejection. This duality of function is important if clinicians are to design immunotherapy strategies which will achieve the true potential and result in improved survival in MM.
Collapse
Affiliation(s)
- G Cook
- Department of Medicine, University of Glasgow, Royal Infirmary, UK
| | | |
Collapse
|
152
|
Bastien Y, Toledano BJ, Mehio N, Cameron L, Lamoukhaid B, Renzi P, Hamid Q, Mazer BD. Detection of Functional Platelet-Activating Factor Receptors on Human Tonsillar B Lymphocytes. THE JOURNAL OF IMMUNOLOGY 1999. [DOI: 10.4049/jimmunol.162.9.5498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
Although platelet-activating factor (PAF) receptors have been found on B lymphoblastoid cell lines, the action of PAF on freshly isolated human B cells has not been clearly demonstrated. Using a sensitive semiquantitative reverse-transcriptase PCR, we have found PAF receptor mRNA expressed by tonsillar B lymphocytes, but little in T lymphocytes. Examination of Percoll-fractionated tonsillar B cells indicated that the low density (primarily germinal center cells) and medium density fractions had approximately twofold more PAF receptor mRNA relative to the high density fraction. PAF (10−7 M) stimulated increases in intracellular Ca2+ that were consistently higher in the low and medium density B lymphocytes compared with high density cells. The PAF receptor antagonist Web 2170 inhibited this. Addition of PAF, but not lyso- or enantio-PAF, induced four- to sixfold greater synthesis of IgM and IgG in low and medium density cells compared with unstimulated controls, but had little effect on Ig production by high density cells. To investigate how PAF may influence Ig synthesis, PAF-stimulated B cells were examined for production of the Th2-type cytokines IL-4 and IL-13. PAF induced IL-4 and IL-13 mRNA expression in 17% of CD20+ cells, and IL-4 was detected in cell supernatants after 48–72 h of culture. Together, these data strongly suggest that functional PAF receptors are expressed on B cells in tonsils.
Collapse
Affiliation(s)
- Yolande Bastien
- *Division of Allergy and Immunology, Montreal Children’s Hospital, McGill University/Montreal Children’s Hospital Research Institute, and
- †Meakins Christie Laboratories, McGill University, Montreal, Quebec, Canada
| | - Baruch J. Toledano
- *Division of Allergy and Immunology, Montreal Children’s Hospital, McGill University/Montreal Children’s Hospital Research Institute, and
- †Meakins Christie Laboratories, McGill University, Montreal, Quebec, Canada
| | - Noha Mehio
- †Meakins Christie Laboratories, McGill University, Montreal, Quebec, Canada
| | - Lisa Cameron
- †Meakins Christie Laboratories, McGill University, Montreal, Quebec, Canada
| | | | - Poalo Renzi
- †Meakins Christie Laboratories, McGill University, Montreal, Quebec, Canada
| | - Qutayba Hamid
- †Meakins Christie Laboratories, McGill University, Montreal, Quebec, Canada
| | - Bruce D. Mazer
- *Division of Allergy and Immunology, Montreal Children’s Hospital, McGill University/Montreal Children’s Hospital Research Institute, and
- †Meakins Christie Laboratories, McGill University, Montreal, Quebec, Canada
| |
Collapse
|
153
|
French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999; 5:548-53. [PMID: 10229232 DOI: 10.1038/8426] [Citation(s) in RCA: 257] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
CD40 is essential in enabling antigen-presenting cells to process and present antigen effectively to T cells. We demonstrate here that when antibody against CD40 is used to treat mice with syngeneic lymphoma, a rapid cytotoxic T-cell response independent of T-helper cells occurs, with tenfold expansion of CD8+ T cells over a period of 5 days. This response eradicates the lymphoma and provides protection against tumor rechallenge without further antibody treatment. Thus, it seems that by treating mice with monoclonal antibody against CD40, we are immunizing against syngeneic tumors. The phenomenon proved reproducible with two antibodies against CD40 (3/23 and FGK-45) in three CD40+ lymphomas (A20, A31 and BCL1) and gave partial protection in one of two CD40- lymphomas (EL4 and Ten1). Although the nature of the target antigens on these lymphomas is unknown, CD8+ T cells recovered from responding mice showed powerful cytotoxic activity against the target B-cell lymphoma in vitro.
Collapse
Affiliation(s)
- R R French
- Lymphoma Research Unit, Tenovus Laboratory, General Hospital, Southampton, UK
| | | | | | | |
Collapse
|
154
|
Garraud O, Mollis SN, Holland SM, Sneller MC, Malech HL, Gallin JI, Nutman TB. Regulation of immunoglobulin production in hyper-IgE (Job's) syndrome. J Allergy Clin Immunol 1999; 103:333-40. [PMID: 9949327 DOI: 10.1016/s0091-6749(99)70510-5] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND The hyper-IgE (HIE), or Job's, syndrome is a rare, complex disorder characterized by high levels of serum IgE in childhood and chronic dermatitis with recurrent, often severe sinopulmonary and skin infections. Although the etiology of HIE syndrome is unknown, there is evidence that patients with HIE have abnormalities in cellular immune responses, as well as in the production of polyclonal and antigen-specific antibodies. Furthermore, there appears to be a common (but still undefined) mechanism underlying the regulation of IgE and IgG4 in this condition. OBJECTIVE We sought to assess the role of cytokines or cytokine receptor blockade in regulating IgE and IgG4 production in HIE. METHODS PBMCs were isolated from patients with HIE (n = 9) and normal individuals (n = 8), and IgE and IgG4 production was assessed spontaneously, in the presence of recombinant IL-4, IL-13, IL-6, IL-8, IL-12, and IFN-gamma, under conditions in which the IL-4R was blocked or when these cytokines were neutralized by specific monoclonal or polyclonal antibodies. RESULTS In PBMCs from patients with HIE, a significant (P <.01) reduction in the spontaneously produced IgE (and IgG4) was induced by either IFN-gamma or IL-12, although neither cytokine could totally abrogate the immunoglobulin production. Whereas spontaneous IgE (and IgG4) production was not affected by exogenous IL-4 and IL-13, neutralizing antibodies to IL-4 and IL-13 also significantly (P <.01) reduced the production of IgE and IgG4, a finding supported by the observation of increased expression of IgE germline transcripts in these patients. In contrast to the neutralization of IL-4 and IL-13 protein, anti-IL-4R antibodies or soluble IL-4R completely suppressed IgE and IgG4 production in HIE. Similarly, IL-8 or antibodies to IL-6 and TNF-alpha, cytokines known to affect IL-4-dependent IgE production, completely inhibited both IgE and IgG4 production. CONCLUSION These data show that overproduction of IgE and IgG4 can be regulated by a number of cytokines affecting the IL-4-dependent pathway of IgE/IgG4 production in HIE and suggest new targets for therapeutic intervention.
Collapse
Affiliation(s)
- O Garraud
- Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892-0425, USA
| | | | | | | | | | | | | |
Collapse
|
155
|
Schultze JL, Michalak S, Lowne J, Wong A, Gilleece MH, Gribben JG, Nadler LM. Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses. J Exp Med 1999; 189:1-12. [PMID: 9874559 PMCID: PMC1887700 DOI: 10.1084/jem.189.1.1] [Citation(s) in RCA: 92] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/1998] [Revised: 10/27/1998] [Indexed: 11/26/2022] Open
Abstract
Interleukin (IL)-12 is expressed mainly in antigen-presenting cells after challenge with microbial material or after CD40 activation. Although IL-12 was cloned from human Epstein-Barr virus (EBV)-transformed B cell lines, surprisingly, CD40 ligation on murine B cells did not lead to IL-12 production, suggesting that murine B cells do not produce IL-12. Here we demonstrate that a subset of human tonsillar B cells can be induced to express and secrete bioactive IL-12. The major stimulus to produce IL-12 in human B cells was CD40 ligation. In contrast, B cell receptor cross-linking did not induce IL-12. Expression of IL-12 after CD40 activation was restricted to CD38(-)IgD+/- non-germinal center (non-GC) B cells. CD40 ligation and interferon (IFN)-gamma exhibited synergistic effects on IL-12 production, whereas IL-10 abrogated and IL-4 significantly inhibited IL-12 production by these B cells. In contrast to IL-12, production of IL-6 is conversely regulated, leading to significant increase after CD40 ligation in the presence of the T helper type 2 (Th2) cytokine IL-4. Cord blood T cells skewed towards either a Th1 or a Th2 phenotype maintained their cytokine expression pattern when restimulated with allogeneic resting B cells. Blockade of CD40 and/or IL-12 during T-B interaction significantly reduced IFN-gamma production by the T cells. This suggests a model whereby B cells produce either IL-12 or IL-6 after contact with T cells previously differentiated towards Th1 or Th2. Furthermore, IL-12 and IL-6 might provide a positive feedback during cognate T-B interactions, thereby maintaining T cells' differentiation pattern during amplification of the immune response.
Collapse
Affiliation(s)
- J L Schultze
- Department of Adult Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
| | | | | | | | | | | | | |
Collapse
|
156
|
Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999; 17:399-408. [PMID: 10458259 DOI: 10.1200/jco.1999.17.1.399] [Citation(s) in RCA: 308] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To review the recent major advances in the molecular and cell biology of B-cell chronic lymphocytic leukemia (B-CLL). METHODS We analyzed the nature of malignant B-CLL B cells and their interactions with the microenvironment. RESULTS B-CLL is a malignancy of a mantle zone-based subpopulation of anergic, self-reactive, activated CD5+ B cells devoted to the production of polyreactive natural autoantibodies. It is the quintessential example of a human malignancy that primarily involves defects in the induction of programmed cell death. An abnormal karyotype is observed in about 50% of patients with B-CLL. Patients with 13q14 abnormalities show heavy somatic mutation and have a benign disease. Trisomy 12 is associated with unmutated VH genes, atypical cellular morphology, and progressive disease. Extended cell survival is further shielded by a kinetic refractoriness likely promoted by abnormalities of the B-cell antigen receptor complex and favored by some cytokines that highlight a reciprocal dialog between malignant B and T cells. Because the tumor cells act as the major accessory cells, the accumulating malignant B-cell population per se is a hurdle to the production of normal antibodies and leads to a progressive and severe hypogammaglobulinemia. Conceivably, in the presence of certain immunoglobulin genes and when the T-cell control becomes deficient, activated malignant B cells may become able to present self-antigens and drive residual normal B cells to produce polyclonal autoantibodies restricted to self-antigens expressed only by blood cells and cause autoimmune cytopenias. CONCLUSION The distinctiveness of B-CLL B cells explains why B-CLL is different from other B-cell tumors and accounts for the development of immune deficiency and autoimmunity.
Collapse
Affiliation(s)
- F Caligaris-Cappio
- Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Ospedale Mauriziano Umberto I, Italy.
| | | |
Collapse
|
157
|
Boulland ML, Meignin V, Leroy-Viard K, Copie-Bergman C, Brière J, Touitou R, Kanavaros P, Gaulard P. Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. THE AMERICAN JOURNAL OF PATHOLOGY 1998; 153:1229-37. [PMID: 9777954 PMCID: PMC1853048 DOI: 10.1016/s0002-9440(10)65667-2] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Several cytokines have been implicated in the pathogenesis of human lymphomas. Among them, interleukin-10 (IL-10) is a pleiotropic cytokine with various biological effects on B and T lymphocytes. Its expression has been essentially studied in B-cell lymphomas, where it appears to act as an autocrine growth factor. BCRF1 (also called viral IL-10), an open reading frame of Epstein-Barr virus, exhibits extensive sequence and functional homologies with human IL-10. Some entities belonging to T- or natural killer (NK)-cell lymphomas are characterized by a frequent association with Epstein-Barr virus. We analyzed 39 cases of peripheral T-cell lymphoma, as well as 7 cases of nasal NK-cell lymphoma, for the presence of IL-10 transcripts by in situ hybridization, to see whether this cytokine was expressed in these tumors and whether its expression could be related to their histological subtype and to the presence of Epstein-Barr virus. Because the riboprobe used for in situ hybridization recognizes both human and viral IL-10, 12 cases were also analyzed by reverse transcription-polymerase chain reaction to verify the human or viral origin of IL-10. It was found that 8 of 11 (73%) anaplastic large cell lymphomas (ALCLs), 2 of 11 (18%) pleomorphic T-cell lymphomas, and 3 of 7 (43%) nasal NK-cell lymphomas exhibited a large number of IL-10-expressing cells, whereas only rare scattered cells were detected in angioimmunoblastic (11 of 11) and in gammadelta T-cell lymphomas (6 of 6). In ALCLs, the pattern of IL-10 mRNA-expressing cells showed an overlapping with the CD30 staining and preferential localization in sinusal and perifollicular areas, thereby suggesting that IL-10-expressing cells were tumor cells. Furthermore, IL-10 transcripts were detected in the SU-DHL-1 anaplastic lymphoma cell line. No correlation with Epstein-Barr virus profile was found, because all cases of ALCL were negative for EBER 1 and 2 genes by in situ hybridization. We confirmed the presence of human IL-10 mRNA by reverse transcription-polymerase chain reaction in ALCLs as well as in NK-cell lymphomas, whereas viral IL-10 was not detected. Thus, human and not viral IL-10 is frequently expressed by tumor cells in ALCLs and nasal NK-cell lymphomas. In view of its function in the proliferation and the differentiation of cytotoxic T and NK cells, and its immunosuppressive properties, IL-10 may have a role in the pathogenesis of these lymphomas.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Animals
- Callithrix
- Child
- Female
- Herpesvirus 4, Human/isolation & purification
- Humans
- In Situ Hybridization
- Interleukin-10/genetics
- Interleukin-10/metabolism
- Killer Cells, Natural/metabolism
- Killer Cells, Natural/pathology
- Lymphoma, Large-Cell, Anaplastic/genetics
- Lymphoma, Large-Cell, Anaplastic/metabolism
- Lymphoma, Large-Cell, Anaplastic/pathology
- Lymphoma, Large-Cell, Anaplastic/virology
- Lymphoma, T-Cell/genetics
- Lymphoma, T-Cell/metabolism
- Lymphoma, T-Cell/pathology
- Lymphoma, T-Cell/virology
- Male
- Middle Aged
- Monocytes/metabolism
- Nose Neoplasms/genetics
- Nose Neoplasms/metabolism
- Nose Neoplasms/pathology
- Nose Neoplasms/virology
- RNA, Messenger/biosynthesis
- RNA, Viral/analysis
- Retrospective Studies
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- M L Boulland
- Département de Pathologie, Hôpital Henri Mondor, Créteil, France
| | | | | | | | | | | | | | | |
Collapse
|
158
|
Grammer AC, Swantek JL, McFarland RD, Miura Y, Geppert T, Lipsky PE. TNF Receptor-Associated Factor-3 Signaling Mediates Activation of p38 and Jun N-Terminal Kinase, Cytokine Secretion, and Ig Production Following Ligation of CD40 on Human B Cells. THE JOURNAL OF IMMUNOLOGY 1998. [DOI: 10.4049/jimmunol.161.3.1183] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
CD40 engagement induces a variety of functional outcomes following association with adaptor molecules of the TNF receptor-associated factor (TRAF) family. Whereas TRAF2, -5, and -6 initiate NF-κB activation, the outcomes of TRAF3-initiated signaling are less characterized. To delineate CD40-induced TRAF3-dependent events, Ramos B cells stably transfected with a dominant negative TRAF3 were stimulated with membranes expressing recombinant CD154/CD40 ligand. In the absence of TRAF3 signaling, activation of p38 and control of Ig production were abrogated, whereas Jun N-terminal kinase activation and secretion of IL-10, lymphotoxin-α, and TNF-α were partially blocked. By contrast, induction of apoptosis, activation of NF-κB, generation of granulocyte-macrophage CSF, and up-regulation of CD54, MHC class II, and CD95 were unaffected by the TRAF3 dominant negative. Together, these results indicate that TRAF3 initiates independent signaling pathways via p38 and JNK that are associated with specific functional outcomes.
Collapse
Affiliation(s)
- Amrie C. Grammer
- *Harold C. Simmons Arthritis Research Center and Departments of Internal Medicine,
| | | | | | - Yasushi Miura
- *Harold C. Simmons Arthritis Research Center and Departments of Internal Medicine,
| | - Thomas Geppert
- *Harold C. Simmons Arthritis Research Center and Departments of Internal Medicine,
| | - Peter E. Lipsky
- *Harold C. Simmons Arthritis Research Center and Departments of Internal Medicine,
| |
Collapse
|
159
|
Moreno B, Woodall CJ, Watt NJ, Harkiss GD. Transforming growth factor-beta 1 (TGF-beta1) expression in ovine lentivirus-induced lymphoid interstitial pneumonia. Clin Exp Immunol 1998; 112:74-83. [PMID: 9566793 PMCID: PMC1904931 DOI: 10.1046/j.1365-2249.1998.00553.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/12/1997] [Indexed: 02/07/2023] Open
Abstract
The aim of this study was to detect the localization of TGF-beta1 protein expression in normal sheep lungs and lungs with interstitial pneumonia associated with infection with maedi-visna virus (MVV). Immunohistochemical localization of TGF-beta1 was determined in 24 lungs of adult sheep naturally infected with MVV and six control lungs of seronegative sheep. The lungs of infected animals showed different lesional degrees: grade 0, no lesions; grade I, mild; grade II, moderate; grade III, severe. In normal lungs, TGF-beta1 was primarily expressed in airway epithelium, bronchial cartilage and glands, endothelial cells and smooth muscle of blood vessels, alveolar macrophages and type II pneumocytes. No staining was observed in alveolar interstitium. In MVV-infected sheep an increased number of positive alveolar and interstitial macrophages and staining of alveolar interstitium was observed in grade I, grade II and some grade III lesions. In grade III lesions an inverse relationship was found between TGF-beta1 staining and smooth muscle hyperplasia. Small lymphoid aggregates, in general, showed strong reactivity, whereas larger ones showed weak reactivity, mainly associated with follicular areas. No significant differences in the staining intensity of airways and blood vessels were observed between control and MVV lungs. The increased expression of TGF-beta1 in early maedi lesions and its down-regulation in more advanced disease suggest the operation of a temporal regulatory mechanism whereby early expression may lead to the smooth muscle hyperplasia which develops during the disease. The striking inverse relationship between TGF-beta1 expression and follicle organization is intriguing and warrants further investigation.
Collapse
Affiliation(s)
- B Moreno
- Department of Veterinary Pathology, Royal (Dick) School of Veterinary Studies, University of Edinburgh, UK
| | | | | | | |
Collapse
|
160
|
Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998; 28:914-25. [PMID: 9541587 DOI: 10.1002/(sici)1521-4141(199803)28:03<914::aid-immu914>3.0.co;2-c] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Bee venom phospholipase A2 (PLA) represents the major allergen and antigen in allergic and non-allergic individuals sensitized to bee sting. We have studied specific activation of peripheral T cells by different structural and conformational variants of PLA and secretion of cytokines regulating IgE and IgG4 antibody (Ab) formation. PLA molecules expressing the correctly folded tertiary structure, which show high affinity to membrane phospholipids and were recognized by Ab from bee sting allergic patients, induced high IL-4, IL-5 and IL-13 production in peripheral blood mononuclear cell cultures. In contrast, non-refolded recombinant PLA (rPLA) and reduced and alkylated native PLA (nPLA) induced more IFN-gamma and IL-2 and higher proliferative responses. Differences in proliferation and cytokine patterns among correctly folded and non-refolded PLA resulted from conformation-dependent involvement of different antigen-presenting cell (APC) types. Antigen (Ag)-presenting B cells recognized PLA only in its natural conformation, stimulated Th2 type cytokines and induced IgE Ab. Non-refolded PLA was recognized, processed and presented exclusively by monocytes and induced a Th1 dominant cytokine profile leading to IgG4 production by B cells. The possibility that production of particular cytokine patterns and Ig isotype was influenced by the enzymatic activity of PLA was excluded by using enzymatically inactive H34Q point-mutated, refolded rPLA. These findings demonstrate the decisive role of specific Ag recognition by different APC, depending on structural features, membrane phospholipid binding property and the existence of conformational B cell epitopes, in the differential regulation of memory IgE and IgG4 Ab. Furthermore, they show that a change from IgE-mediated allergy to normal immunity against a major allergen can be induced by rPLA variants that are not recognized by specific Ab and B cells but still carry the T cell epitopes. These features may enable new applications for safer immunotherapy.
Collapse
Affiliation(s)
- C A Akdis
- Swiss Institute of Allergy and Asthma Research, Davos, Switzerland.
| | | | | | | | | |
Collapse
|
161
|
Willenborg DO, Staykova MA. Approaches to the treatment of central nervous system autoimmune disease using specific neuroantigen. Immunol Cell Biol 1998; 76:91-103. [PMID: 9553781 DOI: 10.1046/j.1440-1711.1998.00721.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The ultimate aim in the treatment of autoimmune disease is to restore self-tolerance to the autoantigen(s) in question. In lieu of this ideal result, the conversion of a destructive or pathogenic autoimmune response into one of benign autoimmunity would also be highly desirable. In either case the use of the antigenic epitope, which is the target of the destructive immune response, would ideally be employed so as to give specificity to the protection without the need for long-term immunosuppression. This review describes a number of different approaches using various forms, doses, and routes of injection of specific neuroantigen to inhibit the different clinical varieties of autoimmune encephalomyelitis in a number of animal models; all done with the view to translating the findings into the clinic for the treatment of multiple sclerosis. We conclude that any treatment strategy for multiple sclerosis (MS) must have a number of features: it must be clinically acceptable, specific, long-lasting, require only short-term treatment, able to shunt off ongoing disease, and have the potential to prevent or deal with epitope spreading. Few of the approaches we describe fulfill all of these criteria. We suggest that investigations of new adjunctive agents to be used with a specific antigen be pursued, and that currently the use of chimeric proteins or DNA vaccination with or without the new adjunctives may hold the most hope for the future.
Collapse
Affiliation(s)
- D O Willenborg
- Neurosciences Research Unit, Canberra Hospital, Australian Capital Territory, Australia.
| | | |
Collapse
|
162
|
Kitze B, Usuku K, Yamano Y, Yashiki S, Nakamura M, Fujiyoshi T, Izumo S, Osame M, Sonoda S. Human CD4+ T lymphocytes recognize a highly conserved epitope of human T lymphotropic virus type 1 (HTLV-1) env gp21 restricted by HLA DRB1*0101. Clin Exp Immunol 1998; 111:278-85. [PMID: 9486393 PMCID: PMC1904927 DOI: 10.1046/j.1365-2249.1998.00497.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/16/1997] [Indexed: 02/06/2023] Open
Abstract
HTLV-1 causes two distinct human diseases, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T cell leukaemia/lymphoma (ATL). Persistently infected individuals carry a risk of <1% of developing either disease. These basic epidemiological data imply that virus-host interactions, especially immunogenetic factors, influence the outcome of infection. Several studies showed that the HLA class II DR1 DQ5 haplotype is over-represented in HAM/TSP, but rare in ATL. Therefore, we selected four patients with HAM/TSP and one seronegative control who all carried the HLA DR1 DQ5 haplotype. We analysed the CD4+ T lymphocyte response against eight synthetic peptides of HTLV-1 envelope (env) glycoprotein gp21, a crucial target antigen in HAM/TSP. The first of two immunodominant epitopes corresponded to a domain of the HTLV-1 envelope protein which had previously been shown to be essential for HTLV-1 envelope function. The second immunodominant epitope overlapped a highly conserved sequence of the retroviral transmembrane envelope protein. DR1 (DRB1*0101)-restricted T lymphocytes were activated by the conserved peptide sequence in nanomolar concentrations. In contrast, this conserved sequence can also induce non-specific, cAMP-mediated immunosuppressive effects on T cells when added in micromolar concentrations to culture media, as shown by Haraguchi S, Good RA, James-Yarish M, Cianciolo GJ, Day NK, Proc Natl Acad Sci USA 1995; 92:5568-71. Hence, HTLV-1 env gp21 might exert either stimulating immunological or immunosuppressive effects in HTLV-1-infected individuals, depending on the level of its expression and the presence of HLA DRB1*0101.
Collapse
MESH Headings
- Amino Acid Sequence
- CD4-Positive T-Lymphocytes/immunology
- CD4-Positive T-Lymphocytes/metabolism
- Cell Line
- Conserved Sequence
- Epitopes, B-Lymphocyte/immunology
- Epitopes, B-Lymphocyte/metabolism
- Epitopes, T-Lymphocyte/immunology
- Epitopes, T-Lymphocyte/metabolism
- Gene Products, env/immunology
- Gene Products, env/metabolism
- HLA-DR Antigens/immunology
- HLA-DR Antigens/metabolism
- HLA-DRB1 Chains
- Humans
- Immunodominant Epitopes/immunology
- Immunodominant Epitopes/metabolism
- Molecular Sequence Data
- Retroviridae Proteins, Oncogenic/immunology
- Retroviridae Proteins, Oncogenic/metabolism
- Sequence Homology, Amino Acid
- env Gene Products, Human Immunodeficiency Virus
Collapse
Affiliation(s)
- B Kitze
- Centre for Chronic Viral Diseases, Third Department of Internal Medicine, Faculty of Medicine, Kagoshima University, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|